- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01259830
Effectiveness of Etoricoxib as an Additive Analgesic to Epidural Analgesia in Colon or Rectal Fast-track Surgery
A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Effectiveness of Etoricoxib as an Additive Analgesic to Epidural Analgesia in Colon or Rectal Fast-track Surgery
Post-operative pain after laparoscopic colon and rectal surgery in fast-track design.
A fast-track program is an evidence-based, multimodal approach for patients undergoing surgery to reduce perioperative morbidity, hospital stay and cost and to increase patient centered well-being. Optimized pain relief is a core component of any fast-track regimen.
In this context epidural analgesia has become the standard of care for early postoperative pain therapy.
However, it is debated whether non-opioid analgesics should be given as adjuncts when epidural analgesia is already present.
The purpose of this study is to demonstrate that the administration of etoricoxib 120mg additionally to the clinical routine therapy (epidural catheter) reduces the post-operative pain level during movement after laparoscopic colon surgery in the fast-track design.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A fast-track program is an evidence-based, multimodal approach for patients undergoing surgery to reduce perioperative morbidity, hospital stay and cost and to increase patient centered well-being. Particularly in visceral surgery of the colon it is gaining widespread acceptance (Schwenk 2009). Optimized pain relief is a core component of any fast-track regimen (Kehlet and Wilmore 2008). In this context epidural analgesia has become the standard of care for early postoperative pain therapy (Hasenberg 2009), providing superior pain relief compared to parenteral opioids (Block 2001).
However, it is debated whether non-opioid analgesics should be given as adjuncts when epidural analgesia is already present. Some studies have found reduced pain using NSAID as adjunct (Scott 1994), leading to a positive recommendation in the German guidelines for postoperative pain therapy (S3-Leitlinie). However, other studies (Mogensen 1992) have not found an effect of non-opioids in addition to epidural analgesia. Further studies are also needed to assess whether nonopioid adjuncts can facilitate the change from epidural to systemic analgesia (typically on the 2nd or 3rd postoperative day) and reduce opioid consumption during the days after catheter removal.
Fast-track surgery is a multi-model process, and every step in this process needs to be fine-tuned to yield best results (Langelotz 2005). Until now studies have compared only groups with either epidural or systemic analgesia, but for optimal recovery a sequential approach with a combination of both is probably a better choice. A typical multimodal analgesia regimen after removal of an epidural at our institution consists of acetaminophen and ibuprofen. Opioids are avoided if possible, but are added if needed. An improved non-opioid analgesia regimen is a sought-after goal in this fast-track-phase. The study is controlled in terms of the type of surgery (laparoscopic colon and rectal surgery) and all factors of the multimodal analgesia treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10115
- St. Hedwig Kliniken Berlin GmbH, Department of Anesthesiology and Intensive Care Medicine
-
Berlin, Germany, 10365
- Department of Anesthesiology, Sana-Klinikum Lichtenberg, Oskar-Ziethen-Krankenhaus
-
Berlin, Germany, 13353
- Department of Anesthesiology and Intensive Care Medicine, Campus Virchow Klinikum/Campus Charité Mitte, Charité Universitätsmedizin
-
Minden, Germany, 32429
- Department of Anesthesiology, Johannes Wesling Klinikum Minden Mühlenkreiskliniken (AöR)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- aged 18 or over
- written informed consent
- no inclusion in other medical studies according to the AMG (German drug law) during the study period
- realization of colon or rectal surgery in the fast track design after clinical standards including an epidural catheter
Exclusion Criteria:
- ASA status IV-V
- allergy against etoricoxib, other components or other NSAID
- coronary heart disease
- heart insufficiency NYHA II-IV
- cerebrovascular disease
- peripheral arterial occlusive disease
- untreated arterial hypertonus
- active peptic ulcera or active gastrointestinal bleeding
- minor to severe liver dysfunction (beginning from Child - Plugh - Classification A)
- kidney insufficiency
- inflammatory bowel disease
- pregnancy (positive hCG laboratory test) or lactation
- Women of child-bearing potential who are not using a highly effective contraception method with a pearl-index < 1 during study participation and for at least 3 consecutive months after study inclusion.
- placement in an institution on order of an official authority
- missing consent for saving and passing on pseudonymous data
- hereditary galactose-intolerance, lactase deficit, glucose-galactose-malabsorption
- no correct epidural catheter placement within 48 h after surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Sugar pill
|
P Tablet White Lichtenstein over encapsulated; Perioperatively 6 days 1 tablet for oral use
|
Experimental: Arcoxia® 120 mg
|
Arcoxia® over encapsulated 120 mg; Perioperatively 6 days 1 tablet (Arcoxia® 120 mg) for oral use
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary end point of the study is the average pain level (scale 0-10) in the area of surgery during movement (walking a fixed number of steps) under active epidural analgesia, at the third day following laparoscopic colon or rectal surgery.
Time Frame: Third postoperative day
|
To demonstrate that the administration of etoricoxib 120mg additionally to the clinical routine therapy (epidural catheter) reduces the post-operative pain level during movement at the third day after laparoscopic colon or rectal surgery in the fast-track design.
|
Third postoperative day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post-operative pain level during movement in the first 2 days after laparoscopic colon or rectal surgery.
Time Frame: In the first 2 days after laparoscopic colon or rectal surgery
|
In the first 2 days after laparoscopic colon or rectal surgery
|
|
Post-operative pain level during rest in the first 2 days after laparoscopic colon or rectal surgery.
Time Frame: In the first 2 days after laparoscopic colon or rectal surgery
|
In the first 2 days after laparoscopic colon or rectal surgery
|
|
Post-operative pain level during rest and movement from the third (one day after epidural catheter removal) until the fifth day after laparoscopic colon or rectal surgery
Time Frame: In the first three days after epidural catheter removal
|
In the first three days after epidural catheter removal
|
|
Incidence of pain events and the average pain intensity in body parts outside of the area of operations.
Time Frame: In the first three days after epidural catheter removal
|
In the first three days after epidural catheter removal
|
|
Incidence of new organ dysfunctions
Time Frame: In the first nine days after laparoscopic colon or rectal surgery
|
Organ dysfunctions (cardiovascular, gastrointestinal, renal, respiratory, cognitive, infective)
|
In the first nine days after laparoscopic colon or rectal surgery
|
Postoperative LOS
Time Frame: Period of hospital stay, an exspected average of seven days
|
Period of hospital stay, an exspected average of seven days
|
|
Patients level of satisfaction
Time Frame: In the first five days after laparoscopic colon or rectal surgery
|
In the first five days after laparoscopic colon or rectal surgery
|
|
Incidence of side effects
Time Frame: In the first nine days after laparoscopic colon or rectal surgery
|
Side effects by IMP
|
In the first nine days after laparoscopic colon or rectal surgery
|
Postoperative intensive care unit stay
Time Frame: Period of intensive care unit stay, an exspected average of one day
|
Period of intensive care unit stay, an exspected average of one day
|
|
Amount and frequency of intake of rescue medication
Time Frame: In the first five days after laparoscopic colon or rectal surgery
|
In the first five days after laparoscopic colon or rectal surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Claudia Spies, MD, Prof., Dept. of Anesthesiology and Intensive Care, Charité, Universitätsmedizin Berlin
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Postoperative Complications
- Pain
- Neurologic Manifestations
- Pain, Postoperative
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Cyclooxygenase 2 Inhibitors
- Etoricoxib
Other Study ID Numbers
- Etoricoxib-fast-track
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post-operative Pain
-
Kaohsiung Medical University Chung-Ho Memorial...Not yet recruitingPostoperative Complications | Chronic Post Operative Pain | Acute Post Operative PainTaiwan
-
MercyOne Des Moines Medical CenterTerminatedPost Operative Pain | Post Operative Nausea and VomitingUnited States
-
E-DA HospitalNot yet recruitingCesarean Section | Post Operative Pain, Acute | Post Operative Pain, ChronicTaiwan
-
University of HaifaRecruiting
-
Hospital Universitari Vall d'Hebron Research InstituteRecruitingPost Operative PainSpain
-
Sohag UniversityNot yet recruitingPost Operative Pain
-
Tribhuvan University Teaching Hospital, Institute...Recruiting
-
Beijing Tide Pharmaceutical Co., LtdThe Third Xiangya Hospital of Central South UniversityNot yet recruitingPain, Post-operativeChina
-
Benaroya Research InstituteRecruitingPost Operative PainUnited States
-
National Cancer Institute, EgyptRecruiting
Clinical Trials on Arcoxia®120 mg
-
Disphar International B.V.WithdrawnComparative BioavailabilityJordan
-
Darnitsa Pharmaceutical CompanyAnapharm BioanalyticsCompletedHealthy Subjects | BioequivalenceTurkey
-
Hoffmann-La RocheChugai Pharmaceutical Co.TerminatedNeuromyelitis Optica Spectrum Disorder | NMOSDUnited States, Korea, Republic of, Italy, Canada, Japan, Turkey
-
IpsenRecruitingPrimary Sclerosing CholangitisUnited States, Spain, Germany, Canada, United Kingdom, Italy, Portugal
-
Eli Lilly and CompanyActive, not recruitingNeoplasms, HematologicUnited States, Germany, Australia, Sweden, France, Spain, Italy, Austria, Canada
-
Pharmtechnology LLCClinPharmInvest, LLCNot yet recruitingBioequivalenceRussian Federation
-
IpsenCompletedAcromegaly | Neuroendocrine TumoursSwitzerland, Austria, Germany
-
Almirall, S.A.Completed
-
GenfitSGS Life Sciences, a division of SGS Belgium NVCompleted